Time-dependent decrement of dermal gadolinium deposits and significant improvement of skin symptoms in a patient with nephrogenic systemic fibrosis after temporary renal failure

Journal of Cutaneous Pathology

Volumn 40, Issue 11, 2013, Pages 935-944

  Schäd, Susanne G ^a   Heitland, Peter ^b   Kühn Velten, W Nikolaus ^b   Gross, Gerd E ^a   Jonas, Ludwig ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b Medizinisches Labor Bremen   (Germany)

Author keywords

electron microscopy; gadolinium; inductively coupled plasma mass spectrometry; nephrogenic systemic fibrosis; renal failure

Indexed keywords

CONTRAST MEDIUM; GADOLINIUM;

ARTICLE; CASE REPORT; CHEMICALLY INDUCED DISORDER; CHEMISTRY; ELECTRON MICROSCOPY; HUMAN; INDUCTIVELY COUPLED PLASMA-MASS SPECTROMETRY; KIDNEY FAILURE; MALE; MIDDLE AGED; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; SKIN; TIME;

ELECTRON MICROSCOPY; GADOLINIUM; INDUCTIVELY COUPLED PLASMA-MASS SPECTROMETRY; NEPHROGENIC SYSTEMIC FIBROSIS; RENAL FAILURE;

CONTRAST MEDIA; GADOLINIUM; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MICROSCOPY, ELECTRON; MIDDLE AGED; NEPHROGENIC FIBROSING DERMOPATHY; RENAL INSUFFICIENCY; SKIN; TIME;

EID: 84885947606     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/cup.12214     Document Type: Article

References (28)

1. Elmholdt TR, Pedersen M, Jorgensen B, et al. Nephrogenic systemic fibrosis is only found among gadolinium-exposed kidney-insufficient patients: a case-control study from Denmark. Br J Dermatol 2011; 165: 828.
2. Cowper SE, Robin HS, Steinberg SM, et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000; 356: 1000.
3. Cowper SE, Su LD, Bhawan J, et al. Nephrogenic fibrosing dermopathy. Am J Dermatopathol 2001; 23: 383.
4. Cowper SE,. Nephrogenic systemic fibrosis [ICNSFR Website]. 2001-2009. http://www icnsfr.org
5. Daram SR, Cortese CM, Bastani B,. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: report of a new case with literature review. Am J Kidney Dis 2005; 46: 754.
6. Grobner T,. Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006; 21: 1104.
7. Lemy AA, del Marmol V, Kolivras A, et al. Revisiting nephrogenic systemic fibrosis in 6 kidney transplant recipients: a single-center experience. J Am Acad Dermatol 2010; 63: 389.
8. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006; 17: 2359.
9. Goffin E, Schroeder JA, Weingart C, et al. Absence of gadolinium deposits in the peritoneal membrane of patients with encapsulating peritoneal sclerosis. Nephrol Dial Transplant 2010; 25: 1334.
10. High WA, Ayers RA, Chandler J, et al. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007; 56: 21.
11. High WA, Ayers RA, Cowper SE,. Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007; 56: 710.
12. Schroeder JA, Weingart C, Coras B, et al. Ultrastructural evidence of dermal gadolinium deposits in a patient with nephrogenic systemic fibrosis and end-stage renal disease. Clin J Am Soc Nephrol 2008; 3: 968.
13. Brisch M, Schneider T, Requena L, et al. Nephrogenic fibrosing dermopathy. J Dtsch Dermatol Ges 2003; 1: 464.
14. Cowper SE,. Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol 2003; 15: 785.
15. Marckmann P, Skov L, Rossen K, et al. Clinical manifestation of gadodiamide-related nephrogenic systemic fibrosis. Clin Nephrol 2008; 69: 161.
16. High WA, Ranville JF, Brown M, et al. Gadolinium deposition in nephrogenic systemic fibrosis: an examination of tissue using synchrotron x-ray fluorescence spectroscopy. J Am Acad Dermatol 2010; 62: 38.
17. Khurana A, Greene JF Jr, High WA,. Quantification of gadolinium in nephrogenic systemic fibrosis: re-examination of a reported cohort with analysis of clinical factors. J Am Acad Dermatol 2008; 59: 218.
18. Cowper SE,. Nephrogenic systemic fibrosis: the nosological and conceptual evolution of nephrogenic fibrosing dermopathy. Am J Kidney Dis 2005; 46: 763.
19. Basak P, Jesmajian S,. Nephrogenic systemic fibrosis: current concepts. Indian J Dermatol 2011; 56: 59.
20. Baron PW, Cantos K, Hillebrand DJ, et al. Nephrogenic fibrosing dermopathy after liver transplantation successfully treated with plasmapheresis. Am J Dermatopathol 2003; 25: 204.
21. Gilliet M, Cozzio A, Burg G, et al. Successful treatment of three cases of nephrogenic fibrosing dermopathy with extracorporeal photopheresis. Br J Dermatol 2005; 152: 531.
22. Duffy KL, Green L, Harris R, et al. Treatment of nephrogenic systemic fibrosis with Re-PUVA. J Am Acad Dermatol 2008; 59: S39.
23. Brenner M, Herzinger T, Berking C, et al. Phototherapy and photochemotherapy of sclerosing skin diseases. Photodermatol Photoimmunol Photomed 2005; 21: 157.
24. Cuffy MC, Singh M, Formica R, et al. Renal transplantation for nephrogenic systemic fibrosis: a case report and review of the literature. Nephrol Dial Transplant 2011; 26: 1099.
25. Abraham JL, Thakral C, Skov L, et al. Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis. Br J Dermatol 2008; 158: 273.
26. Pao VY, Chang S, Shoback DM, et al. Hypercalcemia and overexpression of CYP27B1 in a patient with nephrogenic systemic fibrosis: clinical vignette and literature review. J Bone Miner Res 2009; 24: 1135.
27. Steger-Hartmann T, Raschke M, Riefke B, et al. The involvement of pro-inflammatory cytokines in nephrogenic systemic fibrosis-a mechanistic hypothesis based on preclinical results from a rat model treated with gadodiamide. Exp Toxicol Pathol 2009; 61: 537.
28. Varani J, DaSilva M, Warner RL, et al. Effects of gadolinium-based magnetic resonance imaging contrast agents on human skin in organ culture and human skin fibroblasts. Invest Radiol 2009; 44: 74.